CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CorMedix Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CorMedix Inc
300 Connell Drive, Suite 4200
Phone: (908) 517-9500p:908 517-9500 BERKELEY HEIGHTS, NJ  07922  United States Ticker: CRMDCRMD
Business Summary
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Myron M.Kaplan 80 8/7/2017 4/27/2016
Chief Executive Officer, Director JosephTodisco 49 5/10/2022 3/18/2022
Chief Financial Officer SusanBlum 8/29/2025 8/29/2025
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Melinta Therapeutics LLC 44 Whippany Rd Morristown NJ United States
Cempra Pharmaceuticals, Inc. 44 Whippany Road Morristown NJ United States
Melinta Subsidiary Corp. 44 Whippany Road Morristown NJ United States
Rempex Pharmaceuticals, Inc. 44 Whippany Road Morristown NJ United States
Targanta Therapeutics Corporation 44 Whippany Road Morristown NJ United States

Business Names
Business Name
Cempra Pharmaceuticals, Inc.
CorMedix Europe GmbH
CorMedix Inc.
6 additional Business Names available in full report.

General Information
Number of Employees: 64 (As of 2/28/2025)
Outstanding Shares: 74,648,992 (As of 8/5/2025)
Shareholders: 62
Stock Exchange: NASD
Federal Tax Id: 205894890
Fax Number: (302) 636-5454


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, September 9, 2025
Register now for our FAST Rating webinar on September 10 at 2:00 PM ET!